F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES lobbying for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 15, 2026

Expenses

$160,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 5269
RESULTS Act
S 2761
RESULTS Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
HR 5300
Department of State Policy Provisions Act
HR 1108
Diagnostics Testing Preparedness Plan Act of 2025

Lobbying activity 4

Medicare/Medicaid

Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies

Foreign Relations

(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)

Health Issues

(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness

Medical/Disease Research/Clinical Labs

(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough